Original Research Article
Differential CSF Biomarker Levels in APOE-ε4-Positive and -Negative Patients with Memory ImpairmentAndersson C.a, b · Blennow K.d · Johansson S.-E.a · Almkvist O.a, b, c · Engfeldt P.e · Lindau M.f · Eriksdotter-Jönhagen M.a
aDepartment of Neurobiology, Caring Sciences and Society, Karolinska Institutet, bDepartment of Psychology, Karolinska University Hospital Huddinge, and cDepartment of Psychology, Stockholm University, Stockholm, dClinical Neurochemistry Laboratory, Department of Clinical Neuroscience, University of Göteborg, Göteborg, eDepartment of Clinical Medicine, Family Medicine Research Centre, Örebro University, Örebro, and fDepartment of Public Health and Caring Sciences/Geriatrics, Uppsala University Hospital, Uppsala, Sweden
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objectives: To investigate the relationships between episodic memory, APOE genotype, CSF markers (total tau, T-tau; phospho-tau, P-tau; β-amyloid, Aβ42) and longitudinal cognitive decline. Methods: 124 memory clinic patients were retrospectively divided into 6 groups based on (i) episodic memory function (Rey Auditory Verbal Learning Test, RAVLT): severe, moderate or no impairment (SIM, MIM or NIM), and (ii) APOE genotype (Ε4+ or Ε4–). CSF marker levels and cognitive decline were compared across groups. Results: Episodic memory function, according to RAVLT scores, was significantly correlated with CSF marker levels only among Ε4+ subjects and not among Ε4– subjects. When comparing the 6 subgroups, SIM Ε4+ and MIM Ε4+ groups showed significantly lower Aβ42 levels than the other groups. T-tau and P-tau levels were significantly increased in SIM Ε4+ when compared to all the other groups, including the SIM Ε4– group. However, both SIM Ε4+ and SIM Ε4– declined cognitively during the follow-up. Conclusion: It remains to be determined whether APOE genotype affects the expression of biomarkers in CSF, or whether the different biomarker patterns reflect different types of disease processes in patients with progressive cognitive dysfunction.
© 2007 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.